

Special Issue

Vaccines Against Antibiotic Resistant Bacteria: From Bench to Bedside

Message from the Guest Editors

The emergence and global dissemination of bacterial strains from numerous species with resistance to multiple antibiotic classes has increased over the recent years, both in the healthcare and the community setting. Nowadays antimicrobial resistance is a major threat to global public health which can be aggravated in the years to come. To overcome this situation, in addition to existing approaches, novel strategies to fight against the most worrisome species, including both Gram-positive and Gram-negative bacteria, are required. In this context, vaccination has been proven as an effective approach to prevent and reduce bacterial infections. We are pleased to invite you to contribute to this Special Issue with the aim to gather together studies elucidating the potential for vaccines to contribute to reducing the burden of disease of infections caused by antibiotic resistant bacteria, with special focus on pre-clinical studies.

Dr. Mireia López-Siles

Guest Editors

Dr. Michael J. McConnell

Instituto de Salud Carlos III, Madrid, Spain

Dr. Mireia López Siles

Department of Biology, Universitat de Girona, Catalonia, Spain

Dr. Andrés Corral Lugo

National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda, Spain

Deadline for manuscript submissions

closed (31 January 2023)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/94578

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).